A report in the Sept. 27 issue of Science identifies the culprit inducing celiac sprue as a 33-mer peptide of gluten, and a bacterial prolyl endopeptidase which can metabolize this peptide both in vitro and in vivo as a potential strategy for oral supplement therapy.
“When I do presentations about the disease, typically the response I get is, ‘Who is Celiac Sprue?’ ” author Chaitan Khosla, from Stanford University in Palo Alto, California, says in a news release. “This disease has been overlooked in a very serious way by the basic science, clinical, and pharmaceutical communities.”
Khosla’s group performed a combined chemical, physiological, and immunological analysis of gluten proteins called gliadins, and they isolated a single component that triggers the autoimmune response characteristic of celiac sprue. The offending peptide is a chain of 33 amino acids resistant to metabolism by the human gastrointestinal tract. However, research on bacterial digestive enzymes identified a prolyl endopeptidase that can break the chain into innocuous components.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!